

September 17, 2019



## Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes

AUSTIN, Texas, Sept. 17, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a significant milestone in its Nu.Q™ Capture development program: the ability to enrich nucleosomes, and therefore, DNA of tumor versus non-tumor origin. This breakthrough could be used in two ways, firstly to increase specificity in Volition's current assays by removing the background signal and secondly, as an enabling technology in sequencing-based liquid biopsies by enriching nucleosomes of cancer origin from the blood.

Dr. Mark Eccleston, one of the founding Scientists and the Business Development Director at Volition commented, "I am extremely excited that this enabling technology could bridge the gap between Volition's epigenetic profiling approach to early detection and those sequencing approaches that have so far been limited to personalized treatment selection. The recent results could impact the entire sector and highlight Volition as a leader in the field of Clinical epigenetics. The next step in our Nu.Q™ Capture development work, which is underway and will be reported in the coming months, is to determine the level of discrimination of tumor-derived nucleosomes using mass spectrometry, immunoassay and sequencing to provide a complete analysis of cell-free nucleosomes."

Dr. Jake Micallef, Chief Scientific Officer at Volition added, "Volition is focused on advancing the science of epigenetics and has developed an extensive understanding of chromosome and nucleosome structures, particularly in blood. I believe all the work we have done over the past 9 years, including what I believe should be a breakthrough patent we filed last week with the aim of securing Nu.Q™ Capture intellectual property, puts us at the cutting edge of epigenetics."

Volition is currently developing Nu.Q™ products that can detect cancer by measuring circulating nucleosomes in the blood by low-cost immunoassay. In addition to these diagnostic products, Volition, through its Nu.Q™ Capture platform, has developed the ability to enrich nucleosomes of cancer origin from the blood which will be valuable for wider profiling approaches such as mass spectrometry (for target discovery) and simplification of sequencing approaches, opening up the potential for its Nu.Q-Seq approach as well as partnering/licensing opportunities.

### About Volition

Volition is a multi-national life sciences company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.

Volition's research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.

For more information about Volition, visit Volition's website (<http://www.volition.com>) or connect with us via:

Twitter: <https://twitter.com/volition>

LinkedIn: <https://www.linkedin.com/company/volitionrx>

Facebook: <https://www.facebook.com/VolitionRx/>

YouTube: <https://www.youtube.com/user/VolitionRx>

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's

website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

## Media / Investor Contacts

|  |   |
|--|---|
| Louise Batchelor, Volition<br><a href="mailto:mediarelations@volition.com">mediarelations@volition.com</a><br>+44 (0)7557 774620 | Scott Powell, Volition<br><a href="mailto:investorrelations@volition.com">investorrelations@volition.com</a><br>+1 (646) 650 1351 |
| Joseph Green, Edison Advisors<br><a href="mailto:jgreen@edisongroup.com">jgreen@edisongroup.com</a><br>+1 (646) 653 7030         |   |

## Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of Volition's blood-based diagnostic tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases, and the strength of its intellectual property portfolio. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if Volition fails to develop and commercialize diagnostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its associated rapid technological change; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics<sup>TM</sup> and Nu.Q<sup>TM</sup> and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "\$" refer to the legal currency of the United States of America.

View original content:<http://www.prnewswire.com/news-releases/volition-announces-breakthrough-in-enrichment-of-tumor-nucleosomes-300919657.html>

SOURCE VolitionRx Ltd